. 2017 Oct;18(9):704-708.

doi: 10.1111/hiv.12506. Epub 2017 Apr 26.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

P Gantner¹, L Cuzin^{2

3

4}, C Allavena⁵, A Cabie⁶, P Pugliese⁷, M-A Valantin^{8

9}, F Bani-Sadr¹⁰, V Joly¹¹, T Ferry¹², I Poizot-Martin¹³, R Garraffo¹⁴, G Peytavin^{15

16}, S Fafi-Kremer¹, D Rey¹⁷; Dat'AIDS study group

Collaborators, Affiliations

Collaborators

Dat'AIDS study group:
E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet, T Jovelin, N Hall, C Bernaud, P Morineau, V Reliquet, O Aubry, P Point, M Besnier, O Grossi, M Lefebvre, H Hüe, M Cavellec, A Soria, S Pineau, E André-Garnier, A Rodallec, S Brégigeon, O Faucher, V Obry-Roguet, M Orticoni, M J Soavi, I Luquet-Besson, E Ressiot, I Pinot, M J Ducassou, H Bertone, S Gallie, S Trijau, A S Ritleng, A Ivanova, M Guignard, C Blanco-Betancourt, M Alvarez, N Biezunski, A Debard, P Delobel, C Delpierre, C Fourcade, B Marchou, G Martin-Blondel, L Porte, M Mularczyk, D Garipuy, K Saune, I Lepain, M Marcel, E Puntis, C Ceppi, E Cua, J Cottalorda, P Dellamonica, E Demonchy, B Dunais, J Durant, C Etienne, S Ferrando, J G Fuzibet, K Risso, V Mondain, A Naqvi, N Oran, I Perbost, S Pillet, B Prouvost-Keller, C Pradier, S Wehrlen-Pugliese, E Rosenthal, S Sausse, P M Roger, Ph Choisy, S Vandame, Th Huleux, F Ajana, I Alcaraz, V Baclet, T H Huleux, H Melliez, N Viget, M Valette, E Aissi, Ch Allienne, A Meybeck, B Riff, R Agher, C Katlama, C Duvivier, Y Yazdanpanah, R Landman, C Mackoumbou-Nkouka, F Louni, Z Julia, C Charpentier, D Descamps, L Cotte, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, P Miailhes, T Perpoint, I Schlienger, F Dahoud, J Lippmann, E Braun, J Koffi, C Longuet, V Guéripel, C Augustin-Normand, S Degroodt, M L Batard, C Bernard-Henry, C Cheneau, E de Mautort, P Fischer, M Partisani, M Priester, F Bani-Sadr, C Rouger, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, D Lebrun

Affiliations

¹ Virology Laboratory, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
² INSERM, UMR 1027, Toulouse, France.
³ Université de Toulouse III, Toulouse, France.
⁴ CHU Toulouse, COREVIH Toulouse, Toulouse, France.
⁵ Infectious Diseases Department, CHU de Nantes, Nantes, France.
⁶ Infectious Diseases Department, CHU de Fort-de-France, Martinique, France.
⁷ Infectious Diseases Department, CHU de Nice, Nice, France.
⁸ Infectious Diseases Department, APHP Hôpital Pitié Salpêtrière, Paris, France.
⁹ Institut Pierre Louis d'épidémiologie et de Santé Publique (UMRS 1136), UPMC Univ Paris 06, INSERM, Sorbonne Universités, Paris, France.
¹⁰ Infectious Diseases Department, CHU de Reims, Reims, France.
¹¹ Infectious Diseases Department, APHP Hôpital Bichat, Paris, France.
¹² Infectious Diseases Department, Hospices civils de Lyon, Lyon, France.
¹³ APHM Hôpital Sainte-Marguerite, Immuno-Hematology Clinic, Aix-Marseille University, Marseille, France.
¹⁴ Pharmacology Laboratory, CHU de Nice, Nice, France.
¹⁵ AP-HP, Pharmacology Laboratory, Hôpital Bichat-Claude Bernard, Paris, France.
¹⁶ IAME, UMR 1137, Sorbonne Paris Cité, INSERM, Université Paris Diderot, Paris, France.
¹⁷ Le Trait d'Union, HIV-Infection Care Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

PMID: 28444816
DOI: 10.1111/hiv.12506

Free article

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

P Gantner et al. HIV Med. 2017 Oct.

Free article

. 2017 Oct;18(9):704-708.

doi: 10.1111/hiv.12506. Epub 2017 Apr 26.

Authors

Collaborators

Dat'AIDS study group:
E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet, T Jovelin, N Hall, C Bernaud, P Morineau, V Reliquet, O Aubry, P Point, M Besnier, O Grossi, M Lefebvre, H Hüe, M Cavellec, A Soria, S Pineau, E André-Garnier, A Rodallec, S Brégigeon, O Faucher, V Obry-Roguet, M Orticoni, M J Soavi, I Luquet-Besson, E Ressiot, I Pinot, M J Ducassou, H Bertone, S Gallie, S Trijau, A S Ritleng, A Ivanova, M Guignard, C Blanco-Betancourt, M Alvarez, N Biezunski, A Debard, P Delobel, C Delpierre, C Fourcade, B Marchou, G Martin-Blondel, L Porte, M Mularczyk, D Garipuy, K Saune, I Lepain, M Marcel, E Puntis, C Ceppi, E Cua, J Cottalorda, P Dellamonica, E Demonchy, B Dunais, J Durant, C Etienne, S Ferrando, J G Fuzibet, K Risso, V Mondain, A Naqvi, N Oran, I Perbost, S Pillet, B Prouvost-Keller, C Pradier, S Wehrlen-Pugliese, E Rosenthal, S Sausse, P M Roger, Ph Choisy, S Vandame, Th Huleux, F Ajana, I Alcaraz, V Baclet, T H Huleux, H Melliez, N Viget, M Valette, E Aissi, Ch Allienne, A Meybeck, B Riff, R Agher, C Katlama, C Duvivier, Y Yazdanpanah, R Landman, C Mackoumbou-Nkouka, F Louni, Z Julia, C Charpentier, D Descamps, L Cotte, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, P Miailhes, T Perpoint, I Schlienger, F Dahoud, J Lippmann, E Braun, J Koffi, C Longuet, V Guéripel, C Augustin-Normand, S Degroodt, M L Batard, C Bernard-Henry, C Cheneau, E de Mautort, P Fischer, M Partisani, M Priester, F Bani-Sadr, C Rouger, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, D Lebrun

Affiliations

¹ Virology Laboratory, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
² INSERM, UMR 1027, Toulouse, France.
³ Université de Toulouse III, Toulouse, France.
⁴ CHU Toulouse, COREVIH Toulouse, Toulouse, France.
⁵ Infectious Diseases Department, CHU de Nantes, Nantes, France.
⁶ Infectious Diseases Department, CHU de Fort-de-France, Martinique, France.
⁷ Infectious Diseases Department, CHU de Nice, Nice, France.
⁸ Infectious Diseases Department, APHP Hôpital Pitié Salpêtrière, Paris, France.
⁹ Institut Pierre Louis d'épidémiologie et de Santé Publique (UMRS 1136), UPMC Univ Paris 06, INSERM, Sorbonne Universités, Paris, France.
¹⁰ Infectious Diseases Department, CHU de Reims, Reims, France.
¹¹ Infectious Diseases Department, APHP Hôpital Bichat, Paris, France.
¹² Infectious Diseases Department, Hospices civils de Lyon, Lyon, France.
¹³ APHM Hôpital Sainte-Marguerite, Immuno-Hematology Clinic, Aix-Marseille University, Marseille, France.
¹⁴ Pharmacology Laboratory, CHU de Nice, Nice, France.
¹⁵ AP-HP, Pharmacology Laboratory, Hôpital Bichat-Claude Bernard, Paris, France.
¹⁶ IAME, UMR 1137, Sorbonne Paris Cité, INSERM, Université Paris Diderot, Paris, France.
¹⁷ Le Trait d'Union, HIV-Infection Care Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

PMID: 28444816
DOI: 10.1111/hiv.12506

No abstract available

PubMed Disclaimer

Cited by

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
Riccardi N, Del Puente F, Taramasso L, Di Biagio A. Riccardi N, et al. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821657. doi: 10.1177/2325958218821657. J Int Assoc Provid AIDS Care. 2019. PMID: 30798670 Free PMC article.
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV.
Himmel DM, Arnold E. Himmel DM, et al. Pharmaceuticals (Basel). 2020 Jun 11;13(6):122. doi: 10.3390/ph13060122. Pharmaceuticals (Basel). 2020. PMID: 32545407 Free PMC article. Review.
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.
Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, Wit F, Lehmann C, d'Arminio Monforte A, Miró JM, Castagna A, Spagnuolo V, Sönnerborg A, Law M, Hutchinson J, Chkhartishvili N, Bolokadze N, Wasmuth JC, Stephan C, Vannappagari V, Rogatto F, Llibre JM, Duvivier C, Hoy J, Bloch M, Bucher HC, Calmy A, Volny Anne A, Pelchen-Matthews A, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Greenberg L, et al. Clin Infect Dis. 2021 Oct 5;73(7):e2323-e2333. doi: 10.1093/cid/ciaa1878. Clin Infect Dis. 2021. PMID: 33354721 Free PMC article.
Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.
Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F; Dat’AIDS study group. Allavena C, et al. PLoS One. 2018 Sep 21;13(9):e0203895. doi: 10.1371/journal.pone.0203895. eCollection 2018. PLoS One. 2018. PMID: 30240419 Free PMC article.
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
Chu C, Tao K, Kouamou V, Avalos A, Scott J, Grant PM, Rhee SY, McCluskey SM, Jordan MR, Morgan RL, Shafer RW. Chu C, et al. Viruses. 2024 Mar 4;16(3):399. doi: 10.3390/v16030399. Viruses. 2024. PMID: 38543764 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

Collaborators

Affiliations

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

Authors

Collaborators

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical